Feasibility and clinical impact of routine molecular testing of gastrointestinal cancers at a tertiary centre with a multi-gene, tumor-agnostic, next generation sequencing panel

Figures & data

Figure 1. Study flow diagram showing number and type of NGS tests requested in the IRIS network between 2014 and 2019. BC: breast cancer; GI: gastrointestinal; GU: genitourinary; HPB: hepato-biliary-pancreatic; IJB: Institut Jules Bordet; NGS: next-generation sequencing; NSCLC: non-small cell lung cancer.

Figure 2. Requests of NGS tests by tumor type received each year by the molecular pathology laboratory at the Institut Jules Bordet over the study period. BC: breast cancer; GI: gastrointestinal cancers; GU: genitourinary cancers; NSCLC: non-small cell lung cancer.

Figure 3. Turnaround time (days) of the 48-gene Truseq Amplicon Cancer Panel by year over the study period (calculated as the time between reception of test request and report of the results).

Figure 4. Failure rates of the 48-gene Truseq Amplicon Cancer Panel by year over the study period.

Table 1. Association between variables and NGS success in the study population.

Characteristics	Successful NGS N = 972		Failed NGS N = 92		Univariable		Multivariable
					χ2	p Value	OR (95%CI)	p Value
Tumor type					38.63	<.0001	1.24* (0.74−2.09)	.4119*
GI	421	93.8%	26	6.2%
Melanoma	154	94.8%	8	5.2%
NSCLC	152	80.9%	29	19.1%
GU	101	94.1%	6	5.9%
Breast	55	70.9%	16	29.1%
Other	89	92.7%	7	7.3%
Procedure					70.65	<.0001	7.97 (4.24−14.97)	<.0001
Surgery	468	97.5%	12	2.5%
Biopsy	333	83.7%	65	16.3%
FNA	18	64.3%	10	35.7%
Tissue					39.91	<.0001	2.35 (1.44−3.84)	.0006
Primary tumor	472	94.1%	30	5.9%
Metastasis	354	86.1%	57	13.9%
Period					14.00	.0002	1.79 (1.07−2.98)	.0258
Apr 2014 - Oct 2016	339	93.4%	24	6.6%
Nov 2016 - Jun 2019	479	88.4%	63	11.6%

*Variable tumor type dichotomized into GI and non-GI cancers.

CI: confidence interval; FNA: fine-needle aspiration; GI: gastrointestinal cancers; GU: genitourinary cancers; NSCLC: non-small cell lung cancer; OR: odds ratio.

Figure 5. Distribution and proportion by bowel segment of all mutations detected by the 48-gene Truseq Amplicon Cancer Panel in colorectal cancer patients who were managed at the Institut Jules Bordet over the study period (n = 222). The percentages next to each spot indicate the proportion of tumors harboring given mutations within each segment of the bowel.